These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 38246181)

  • 1. [Research progress on immunotherapy based on NK cells for hepatocellular carcinoma].
    Zhu X; Zhou Y; Zhu S
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2024 Jan; 40(1):80-88. PubMed ID: 38246181
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NK cell receptor imbalance and NK cell dysfunction in HBV infection and hepatocellular carcinoma.
    Sun C; Sun H; Zhang C; Tian Z
    Cell Mol Immunol; 2015 May; 12(3):292-302. PubMed ID: 25308752
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The interactions between major immune effector cells and Hepatocellular Carcinoma: A systematic review.
    Schoenberg MB; Li X; Li X; Han Y; Börner N; Koch D; Guba MO; Werner J; Bazhin AV
    Int Immunopharmacol; 2021 Dec; 101(Pt A):108220. PubMed ID: 34673334
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Natural killer cell dysfunction in hepatocellular carcinoma and NK cell-based immunotherapy.
    Sun C; Sun HY; Xiao WH; Zhang C; Tian ZG
    Acta Pharmacol Sin; 2015 Oct; 36(10):1191-9. PubMed ID: 26073325
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of GPC3-Specific Chimeric Antigen Receptor-Engineered Natural Killer Cells for the Treatment of Hepatocellular Carcinoma.
    Yu M; Luo H; Fan M; Wu X; Shi B; Di S; Liu Y; Pan Z; Jiang H; Li Z
    Mol Ther; 2018 Feb; 26(2):366-378. PubMed ID: 29339014
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Natural Killer Cell Dysfunction in Hepatocellular Carcinoma: Pathogenesis and Clinical Implications.
    Sung PS; Jang JW
    Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30463262
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Natural Killer Cells in Liver Disease and Hepatocellular Carcinoma and the NK Cell-Based Immunotherapy.
    Liu P; Chen L; Zhang H
    J Immunol Res; 2018; 2018():1206737. PubMed ID: 30255103
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activity of IL-12/15/18 primed natural killer cells against hepatocellular carcinoma.
    Zhuang L; Fulton RJ; Rettman P; Sayan AE; Coad J; Al-Shamkhani A; Khakoo SI
    Hepatol Int; 2019 Jan; 13(1):75-83. PubMed ID: 30467624
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Natural Killer Cells and Regulatory T Cells Cross Talk in Hepatocellular Carcinoma: Exploring Therapeutic Options for the Next Decade.
    Bozward AG; Warricker F; Oo YH; Khakoo SI
    Front Immunol; 2021; 12():643310. PubMed ID: 33995362
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cisplatin enhances NK cells immunotherapy efficacy to suppress HCC progression via altering the androgen receptor (AR)-ULBP2 signals.
    Shi L; Lin H; Li G; Sun Y; Shen J; Xu J; Lin C; Yeh S; Cai X; Chang C
    Cancer Lett; 2016 Apr; 373(1):45-56. PubMed ID: 26805759
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Liver natural killer cell inoculum for liver transplantation with hepatocellular carcinoma.
    Nishida S; Levi DM; Tzakis AG
    Curr Opin Organ Transplant; 2013 Dec; 18(6):690-4. PubMed ID: 24220052
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Natural Killer Cell Expansion with Autologous Feeder Layer and Anti-CD3 Antibody for Immune Cell Therapy of Hepatocellular Carcinoma.
    Hosseinzadeh F; Ai J; Ebrahimi-Barough S; Seyhoun I; Hajifathali A; Muhammadnejad S; Hosseinzadeh F; Shadnoush M; Dabiri Oskouei F; Verdi J
    Asian Pac J Cancer Prev; 2019 Dec; 20(12):3797-3803. PubMed ID: 31870124
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expanded and Activated Natural Killer Cells for Immunotherapy of Hepatocellular Carcinoma.
    Kamiya T; Chang YH; Campana D
    Cancer Immunol Res; 2016 Jul; 4(7):574-81. PubMed ID: 27197065
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical-scale isolation of interleukin-2-stimulated liver natural killer cells for treatment of liver transplantation with hepatocellular carcinoma.
    Ohira M; Nishida S; Tryphonopoulos P; Tekin A; Selvaggi G; Moon J; Levi D; Ricordi C; Ishiyama K; Tanaka Y; Ohdan H; Tzakis AG
    Cell Transplant; 2012; 21(7):1397-406. PubMed ID: 22469170
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Natural Killer Cells and T Cells in Hepatocellular Carcinoma and Viral Hepatitis: Current Status and Perspectives for Future Immunotherapeutic Approaches.
    Kalathil SG; Thanavala Y
    Cells; 2021 May; 10(6):. PubMed ID: 34071188
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting immune checkpoints: how to use natural killer cells for fighting against solid tumors.
    Ghaedrahmati F; Esmaeil N; Abbaspour M
    Cancer Commun (Lond); 2023 Feb; 43(2):177-213. PubMed ID: 36585761
    [TBL] [Abstract][Full Text] [Related]  

  • 17. hIL-15 gene-modified human natural killer cells (NKL-IL15) augments the anti-human hepatocellular carcinoma effect in vivo.
    Jiang W; Zhang C; Tian Z; Zhang J
    Immunobiology; 2014 Jul; 219(7):547-53. PubMed ID: 24721706
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CNOT7 depletion reverses natural killer cell resistance by modulating the tumor immune microenvironment of hepatocellular carcinoma.
    Ren C; Ren X; Cao D; Zhao H; Zhai Z; Li H; Li Y; Fu X; He J; Zhao H
    FEBS Open Bio; 2020 May; 10(5):847-860. PubMed ID: 32160402
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NK cell marker gene-based model shows good predictive ability in prognosis and response to immunotherapies in hepatocellular carcinoma.
    Li J; Li Y; Li F; Xu L
    Sci Rep; 2023 May; 13(1):7294. PubMed ID: 37147523
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Natural killer cells involved in tumour immune escape of hepatocellular carcinomar.
    Han C; Jiang Y; Wang Z; Wang H
    Int Immunopharmacol; 2019 Aug; 73():10-16. PubMed ID: 31078921
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.